title: The 'death pace' in the CO.17 trial.
abstract: In an era where the cost of care in oncology is rising, suggestions of new frameworks that may help in orienting biomarker discovery are highly desirable. We propose a different perspective for looking at survival data, which we call 'death pace' analysis, which focuses on the variation of the gap between survival curves over time and that may make it easier to identify subpopulations with distinct predictive molecular features. The recently published data on EJC on the impact of the primary colonic site in the CO.17 trial seem to be particularly suitable for the death pace analysis.
authors.affiliation: Medical Oncology Unit, Tor Vergata University Hospital, Viale Oxford, 81, 00133 Rome, Italy. Electronic address: vincenzo.formica@uniroma2.it.
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Formica
authors.affiliation: Unit of Biomedical Robotics and Biomicrosystems, Department of Engineering, Università Campus Bio-Medico di Roma, via Álvaro del Portillo, 21, 00128 Rome, Italy. Electronic address: d.formica@unicampus.it.
authors.forename: Domenico
authors.initials: D
authors.lastname: Formica
authors.affiliation: Dipartimento di Architettura, University of Roma Tre, via della Madonna dei Monti 40, IT-00184 Rome, Italy. Electronic address: formica@uniroma3.it.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Formica
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D006801:Humans; D008297:Male
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents
keywords: Cetuximab; Metastatic colorectal cancer; Predictive factors